查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800170

持續血糖監測 (CGM) 市場：2025 年至 2030 年預測

Continuous Glucose Monitoring (CGM) Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

持續血糖監測 (CGM) 市場預計將從 2025 年的 89.84 億美元成長到 2030 年的 171.19 億美元，複合年成長率為 13.76%。

全球持續血糖監測 (CGM) 市場正經歷強勁成長，這得益於全球糖尿病盛行率的上升。 CGM 系統利用皮下感測器和無線發送器即時追蹤血糖值，為糖尿病管理和調整患者治療方法提供關鍵數據。糖尿病盛行率的上升、技術進步以及政府的支持舉措推動了該市場的發展，使 CGM 成為 2030 年糖尿病治療的關鍵工具。

市場促進因素

糖尿病盛行率不斷上升

久坐的生活方式、胰島素抗性和遺傳因素是糖尿病發生率上升的主要促進因素。連續血糖監測 (CGM) 設備使患者和醫療保健提供者能夠密切監測血糖值，從而促進及時干預。政府計畫和補貼正在改善 CGM 設備的可及性，特別是針對 1 型糖尿病患者，並鼓勵其推廣應用。全球糖尿病患者人數不斷成長，預計到 2030 年將達到 6.43 億，這凸顯了對 CGM 解決方案日益成長的需求，尤其是在患病率快速上升的中低收入國家。

近期動態

企業投入大量資金，加速了動態血糖監測（CGM）的商業化和技術創新。配備更小巧、更可靠感測器的先進CGM設備等產品的推出，正在提升用戶的便利性和準確性。聯網自動化監測系統等創新技術即將問世，這些系統有望與智慧型設備無縫整合。長壽命感測器比傳統的短期系統更易於使用，因此越來越受歡迎，並透過提高患者依從性和降低更換成本，進一步推動市場成長。

市場區隔

由於糖尿病盛行率不斷上升，以及優惠的報銷政策帶來的監測設備需求，糖尿病領域在動態血糖監測 (CGM) 市場佔據主導地位。 CGM 的持續數據提供功能可幫助第 1 型和第 2 型糖尿病患者減少失明、腎衰竭和心血管問題等併發症。無針生物感測器和應用程式整合設備等最尖端科技的引入，正在提升該市場的吸引力，尤其是在糖尿病負擔較重的地區。

區域展望

北美憑藉其日益成長的老年人口、高糖尿病盛行率以及對先進血糖監測解決方案的大量投資，引領CGM市場。美國是CGM市場的主要貢獻者，許多公司正大力投資開發創新的CGM平台。受中國、印度等國糖尿病盛行率上升以及醫療基礎設施改善的推動，亞太地區有望迎來快速成長。歐洲、中東和非洲以及南美也正在透過其區域性努力來滿足糖尿病治療需求，為滿足糖尿病治療需求做出貢獻。

市場展望

預計到2030年，CGM市場將大幅擴張，這得益於糖尿病盛行率的上升、技術創新和政府支持的推動。北美市場的主導地位以及亞太地區的快速成長凸顯了關鍵機會。補貼和成本效益技術的進步正在緩解諸如設備成本高等挑戰。市場發展軌跡凸顯了CGM在全球糖尿病管理轉型中發揮的重要作用，持續的研發將維持這一發展動能。

本報告的主要優點

  • 深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
  • 競爭格局：了解主要企業採用的策略策略，並了解正確策略的市場滲透潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力進行策略決策並在動態環境中開闢新的業務流和收益。
  • 受眾範圍廣：對於新興企業、研究機構、顧問、中小企業和大型企業來說都是有益且具成本效益的。

它有什麼用途？

產業和市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2020 年至 2024 年的歷史數據和 2025 年至 2030 年的預測數據
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測細分市場和區域分析（包括國家）
  • 公司概況（策略、產品、財務、主要發展等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 經營狀況

  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

第5章。按應用分類的持續血糖監測市場

  • 介紹
  • 糖尿病患者
  • 重症患者

6. 持續血糖監測市場（依最終用戶產業）

  • 介紹
  • 醫院
  • 診斷中心和診所
  • 居家護理
  • 其他

7. 持續血糖監測市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第8章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章：公司簡介

  • Dexcom, Inc.
  • Abbott Laboratories
  • Medtronic plc
  • Senseonics Holdings, Inc.
  • Ascensia Diabetes Care
  • Insulet Corporation
  • Roche Diabetes Care, Inc.
  • Tandem Diabetes Care, Inc.
  • GlySens Incorporated
  • Echo Therapeutics, Inc

第10章 附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061611519

The Continuous Glucose Monitoring (CGM) Market is expected to grow from USD 8.984 billion in 2025 to USD 17.119 billion in 2030, at a CAGR of 13.76%.

The global continuous glucose monitoring (CGM) market is experiencing robust growth, driven by the escalating prevalence of diabetes worldwide. CGM systems, utilizing subcutaneous sensors and wireless transmitters to track blood glucose levels in real time, provide critical data for managing diabetes and tailoring patient treatments. The market is propelled by increasing diabetes rates, technological advancements, and supportive government initiatives, positioning CGM as a vital tool in diabetes care through 2030.

Market Growth Drivers

Growing Prevalence of Diabetes

The rising incidence of diabetes, fueled by sedentary lifestyles, insulin resistance, and genetic factors, is a primary driver. CGM devices enable patients and healthcare providers to monitor glucose levels closely, facilitating timely interventions. Government programs and subsidies enhance access to CGM devices, particularly for type 1 diabetes patients, boosting adoption. The projected increase in global diabetes cases-expected to reach 643 million by 2030-underscores the growing demand for CGM solutions, especially in low- and middle-income countries where prevalence is rising rapidly.

Recent Developments

Significant investments by companies are accelerating CGM commercialization and innovation. Product launches, such as advanced CGM devices with smaller, more reliable sensors, are enhancing user convenience and accuracy. Innovations like networked and automated monitoring systems are on the horizon, promising seamless integration with smart devices. Long-lasting sensors, extending usability beyond traditional short-term systems, are gaining traction, further driving market growth through improved patient compliance and reduced replacement costs.

Market Segment Analysis

The diabetes patient segment dominates the CGM market, driven by the increasing prevalence of diabetes and demand for monitoring devices with favorable reimbursement policies. Type 1 and type 2 diabetes patients benefit from CGM's ability to provide continuous data, reducing complications like blindness, kidney failure, and cardiovascular issues. The introduction of cutting-edge technologies, such as needle-free biosensors and app-integrated devices, enhances market appeal, particularly in regions with high diabetes burdens.

Regional Insights

North America leads the CGM market, fueled by a growing geriatric population, high diabetes prevalence, and substantial investments in advanced glucose monitoring solutions. The U.S. is a key contributor, with companies allocating significant funds to develop innovative CGM platforms. The Asia Pacific region is poised for rapid growth, driven by rising diabetes rates and improving healthcare infrastructure in countries like China and India. Europe, the Middle East, Africa, and South America also contribute, with regional efforts to address diabetes care needs.

Market Outlook

The CGM market is set for significant expansion through 2030, driven by diabetes prevalence, technological innovations, and government support. North America's dominance and Asia Pacific's rapid growth highlight key opportunities. Challenges, such as high device costs, are being mitigated through subsidies and advancements in cost-effective technologies. The market's trajectory underscores CGM's critical role in transforming diabetes management globally, with ongoing R&D ensuring sustained momentum.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

USA CGM Market Segmentation:

By Application

  • Diabetes Patients
  • Critical Patients

By End-User Industry

  • Hospitals
  • Diagnostic Centers & Clinics
  • Home Care
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CONTINUOUS GLUCOSE MONITORING MARKET BY APPLICATION

  • 5.1. Introduction
  • 5.2. Diabetes Patients
  • 5.3. Critical Patients

6. CONTINUOUS GLUCOSE MONITORING MARKET BY END-USER INDUSTRY

  • 6.1. Introduction
  • 6.2. Hospitals
  • 6.3. Diagnostic Centers & Clinics
  • 6.4. Home Care
  • 6.5. Others

7. CONTINUOUS GLUCOSE MONITORING MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Dexcom, Inc.
  • 9.2. Abbott Laboratories
  • 9.3. Medtronic plc
  • 9.4. Senseonics Holdings, Inc.
  • 9.5. Ascensia Diabetes Care
  • 9.6. Insulet Corporation
  • 9.7. Roche Diabetes Care, Inc.
  • 9.8. Tandem Diabetes Care, Inc.
  • 9.9. GlySens Incorporated
  • 9.10. Echo Therapeutics, Inc

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations